REWRITE-CAD is a prospective, randomized, multi-center trial assessing the management of asymptomatic participants with a history of PCI or MI who will undergo a blinded CCTA and be randomly assigned to either the test arm in which participants receive the unblinded results of Heartflow AI-CPA or the usual care arm in which participants are blinded to the AI-CPA results.
History of PCI (1 year - 5 years prior to Day 0) and/or history of MI (Type I or II) (1 year - 5 years prior to Day 0)
Patients who do not exhibit symptoms suggestive of CAD
No other clinical CCTA subsequent to MI/PCI but prior to screening
eGFR >45 mL/min per most recent measurement within 90 days
Symptoms suggestive of CAD (e.g. stable angina or dyspnea on exertion)
On PCSK9i and/or inclisiran at baseline
Reduced left ventricular ejection fraction (LVEF) <35%, if known
Prior coronary artery bypass graft (CABG)
Parallel
Heartflow Analysis
DeviceREWRITE-CAD will provide AI-CPA results
Percentage of participants who initiate or intensify lipid-lowering therapy (LLT)
Percentage of participants who initiate or intensify lipid-lowering therapy (LLT)
Percentage of participants who initiate or intensify cardiovascular disease prevention medication therapy
Time to intensification of LLT
% Undergoing lipid testing
Click on the lead sponsor to view all of their trials.
HeartFlow, Inc.
Lead sponsor
Avania
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
